急性冠脉综合征患者经皮冠状动脉介入治疗术后对比剂肾病的防治进展

Prevention of Contrast Induced Nephropathy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

经皮冠状动脉介入治疗是急性冠脉综合征的主要治疗措施。对比剂肾病是经皮冠状动脉介入治疗术后常见并发症之一。对于对比剂肾病缺乏有效治疗措施。术前做好对比剂肾病高危因素评估,识别高危患者,围手术期水化是最为有效的防治措施。另外,他汀类药物和N-乙酰半胱氨酸是研究最多的药物。现对急性冠脉综合征患者经皮冠状动脉介入治疗术后对比剂肾病防治进展进行综述。

Percutaneous coronary intervention has been the main treatment for acute coronary syndrome.Contrast induced nephropathy(CIN)is one of the common complications after percutaneous coronary intervention.There are no effective treatment for CIN.Preoperative assessment of risk factors before emergency percutaneous coronary intervention,identification of high-risk patients,and perioperative adequately hydration are the most effective measures for prevention of CIN.In addition,statins and N-acetylcysteine have been the most extensively studied drugs.This article reviews the progress in the prevention of contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome.